QUEBEC, QUEBEC - May 8, 2008- The management of Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) will propose today at the Annual General Meeting of the Company the addition of Mr. Richard Bordeleau as candidate to Advitech's Board of Directors, thus increasing to six the number of directors from five as stated in the proxy circular. The Annual General meeting will take place at 5:00pm EST at the Germain Des Prés Hotel in Quebec City (Rochette Nadeau Room).
Mr. Bordeleau is currently the Executive Vice-President of BioCad Medical, a high-tech company specialized in computer-aided design and manufacturing of dental and medical prosthesis located in Quebec City. Prior to joining BioCad, from 2001 to September 2007, he was President of Atrium Innovations' Health and Nutrition division after holding the position of Vice-President of that company for one year in 2000. Atrium Innovations is a leading developer, manufacturer and marketer of value-added products for the cosmetics, pharmaceutical, chemical and nutrition industries. Previously, he occupied various positions on the management team of Æterna Zentaris, a biopharmaceutical company where he started in February 1994 as Director of Marketing and become its Senior Vice-President, Corporate Development from 1998 until 2000. Throughout his career, he focused on developing strong organic and external growth through international development, strategic alliances and acquisitions.
"The addition of Mr. Bordeleau will enhance our Board of Directors and help the management of the Company to better identify market opportunities and responses to strategic challenges at Advitech. Mr. Bordeleau will bring his solid experience in the development and expansion of companies to Advitech's Board and management" has stated Renaud Beauchesne, President and Chief Executive Officer of Advitech.
ABOUT ADVITECH INC. www.advitech.com:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex® for the treatment of mild-to-moderate psoriasis.
Advitech has an ongoing research program to develop new applications related to wound healing derived from both its XP-828L and IM technological platforms.